Hepatocellular carcinoma (HCC) is the 5th most frequent tumour disease and, at the same time, the 3rd most frequent cause of death from cancer worldwide. More than 600 000 new patients are diagnosed every year and more than 80% are diagnosed at an advance stage where surgical treatment is not indicated and systemic chemotherapy does not provide longer survival time. Sorafenib is the first substance that provides proven significant prolongation of survival time of HCC patients. This is a multikinase inhibitor with anti-proliferative and anti-angiogenic properties. Its efficacy was shown in the SHARP study that enabled licensing of sorafenib for the therapy of inoperable, metastasizing hepatocellular carcinoma, including patients with liver cirrhosis, functional class Child-Pugh A or B, in more than 60 countries worldwide, including the Czech Republic. The aim of this paper is to provide a comprehensive summary of the current treatment of HCC and, at the same time, to point out some new therapeutic approaches that, in the near future, shall certainly play a major role in the treatment of HCC.

• MeSH
• benzensulfonáty škodlivé účinky   terapeutické užití   MeSH
• fenylmočovinové sloučeniny MeSH
• hepatocelulární karcinom farmakoterapie   MeSH
• lidé MeSH
• nádory jater farmakoterapie   MeSH
• niacinamid analogy a deriváty   MeSH
• protinádorové látky škodlivé účinky   terapeutické užití   MeSH
• pyridiny škodlivé účinky   terapeutické užití   MeSH
• sorafenib MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• benzensulfonáty MeSH
• fenylmočovinové sloučeniny MeSH
• niacinamid MeSH
• protinádorové látky MeSH
• pyridiny MeSH
• sorafenib MeSH